Abbott Laboratories (ABT)

[DewDiligence]

ABT 1Q23 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency) 
 Medical devices*  40%       +12% 
 Diagnostics       28%       -47%† 
 Nutrition         20%       +10%‡ 
 Branded generics  12%       +11%

60% of overall corporate sales were ex-US.

*Includes diabetes care.

†1Q23 COVID-diagnostics sales were $730M (27% of total 1Q23 diagnostic sales); excluding COVID diagnostics, diagnostics sales were +4% YoY.

‡Excluding effect of small divestiture; including the divestiture, nutrition sales were +6% YoY.